Here are Some Higher Beta Stocks
Some higher beta stocks that are at...or very close to being great r/r:
1.
$NEBIUS(NBIS)$: A top 10 position already for me. ARR is at $3B now and I'm modelling ~$70B for 2030.
2.
$Credo Technology Group Holding Ltd(CRDO)$: I want a slightly lower price to add but forecasting ~$10 EPS in FY28 which is 70% CAGR from today which at 35x multiple (0.5x PEG) gives you a $350 stock.
3.
$Bloom Energy Corp(BE)$: Incredible business inflection with operating income +700% and revs +166%.
$NEBIUS(NBIS)$ has cancelled a combustion order to switch to $Bloom Energy Corp(BE)$.
4.
$Cerebras Systems(CBRS)$: Incredible tech and fundamentally different approach to AI compute. ~$190 is where I'd like to see some consolidation.
5.
$Aeva Technologies Inc.(AEVA)$: I think there's a 3x opportunity from ~$18 but just one I'd size accordingly as the CPO/NPO ramp up is quite unknown.
6.
$Amazon.com(AMZN)$: SOTP valuation just makes no sense imo at $2.8T MC.
7.
$Applied Optoelectronics(AAOI)$: Currently trades at 1.6x FY28 forecasted revenue which is one of the lowest out there out of the 2026->2028 ramp up story.
8.
$Invesco Solar ETF(TAN)$: IEA forecasts put solar + wind at ~27% of global electricity generation by 2030. I find some individual solar plays a little risky to pick so $Invesco Solar ETF(TAN)$ is my play here.
9.
$DLocal Limited(DLO)$: Forecasting ~$3.3B in revs by 2030. At 20% NI margins I think a $2 EPS is the forecast which means at 15x EPS (very conservative) we have a 2x from here.
10.
$Tempus AI(TEM)$: Owning the quality data will be the moat for the next 10+ years. Nobody else has unrestricted, identified, multi-modal clinical + molecular data at $Tempus AI(TEM)$'s scale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
